While the US Food and Drug Administration’s decision to issue a Complete Response Letter (CRL) on Merck & Co. and Eisai Co., Ltd.’s bid for accelerated approval of their Keytruda (pembrolizumab) and Lenvima (lenvatinib) combination in first-line unresectable hepatocellular carcinoma (HCC) may be a setback, the companies are already well ahead with another supporting trial in this setting.
But in the meantime, another new combo from Roche has already gained approval in the indication on the back of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?